LYRA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.72 USD | -8.70% |
|
-9.06% | -9.92% |
| Mar. 22 | Lyra Therapeutics Files $300 Million Mixed Shelf Offering | MT |
| Mar. 21 | Lyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Evolution of the average Target Price on Lyra Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
cac5bbd1b.6BQxchWYPU5qZf434M82lXc8rfUt4LnJw2nCSIUjCwY.knNCIUCqbzkwMptPh7h410Vt-L8fj-2FiAavBfdobUSqJ1c_Q_ppHjk6uw~04ff6cc32e8f4bcd942a3ef6c22594cd
More recommendations
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.72
USD
Average target price
12
USD
Spread / Average Target
+154.24%
High Price Target
15
USD
Spread / Highest target
+217.80%
Low Price Target
10
USD
Spread / Lowest Target
+111.86%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Lyra Therapeutics, Inc.
| BTIG | |
| BofA Securities | |
| HC Wainwright | |
| Cantor Fitzgerald |
Trading Rating
Investor Rating
ESG Refinitiv
C
EPS Revisions
- Stock Market
- Equities
- LYRA Stock
- Consensus Lyra Therapeutics, Inc.
